A recent New York Times story described a new fad: "microdosing" GLP-1 anti-obesity drugs like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound). I was asked to discuss the topic on ...

The childhood obesity epidemic in GCC countries has triggered a debate on the potential use of weight-loss medications such ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 504.34% and ...

New research suggests the short-term memory benefits of physical activity may last longer than previously thought, possibly ...

Women worried about losing their locks during chemotherapy can safely take hair-loss drugs during breast cancer care, a new ...

People with diabetes who are taking GLP-1 meds such as Ozempic or Mounjaro may be getting an added bonus: Reductions in their ...

People with diabetes who are taking GLP-1 meds such as Ozempic or Mounjaro may be getting an added bonus: Reductions ...

One particular healthcare stock has shown its ability to soar on good news -- and it's had plenty of it. This year the ...

Zepbound outperformed Wegovy for weight loss in a new clinical trial funded by Eli Lilly & Co., Zepbound's maker.

In a report released on December 6, Terence Flynn from Morgan Stanley maintained a Buy rating on Eli Lilly & Co (LLY – Research Report), ...

This will be one of the first times we can actually celebrate that not only are the dams down, but the salmon have made it ...

Eli Lilly is spending another $3 billion to bulk up manufacturing as the drugmaker seeks to stoke production of some ...